Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taselisib in PIK3CA-Related Overgrowth
NCT03290092Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of taselisib / pictilisib in PIK3CA-related overgrowth spectrum (PROS), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Dose Limiting Toxicities. Started Jul 2017; status: terminated.
02
Drugs
taselisib / pictilisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on NCT03290092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03290092.